Mourabit Halima, Author at MediaMedic

CUA 2024 | Dr. Eamonn Rogers: Patient-Centered Care and Exploring Future Strategies for Prostate Cancer

By Mourabit Halima 2024.10.21

Prostate cancer is a common malignant tumor in elderly men. However, with continuous advancements in diagnostic and treatment strategies, patient survival rates have improved, and patient-centered care has become a key focus in oncology. During the recent CUA Annual Meeting, Urology Frontier invited Dr. Eamonn Rogers from the National University of Ireland to share his thoughts on the future of prostate cancer research, the importance of patient-reported outcomes (PROs), and evolving models of care to meet modern medical challenges.

ESMO 2024丨Dr. Fufu Zheng: Progress in Urologic Cancer Research and Explorations Likely to Change Clinical Practice for Advanced Renal Cancer

By Mourabit Halima 2024.10.21

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is being held from September 13-17 in Barcelona, Spain. Several key studies in the field of urologic cancers have attracted significant attention at the conference. Urology Frontier invited Dr. Fufu Zheng from the Department of Urology at The First Affiliated Hospital , Sun Yat-sen University to provide in-depth analysis of the major research findings presented at the conference. Professor Zheng shared his team’s latest breakthroughs in the field of urology, particularly regarding the frontier advancements in combination therapies for advanced renal cell carcinoma (RCC), while also offering insights into the promising future of RCC treatment.

Revolutionizing NSCLC Treatment: Dr. Baohui Han and Dr. Mitsudomi Unveil New Frontiers in Immunotherapy Strategies

By Mourabit Halima 2024.10.20

The 27th National Clinical Oncology Conference and 2024 CSCO Academic Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. During this event, Dr. Tetsuya Mitsudomi, who has led several large-scale immunotherapy clinical trials, gave an academic report on the latest progress in immunotherapy for NSCLC. Oncology Frontier invited Dr. Baohui Han from Shanghai Chest Hospital to have an in-depth conversation with Dr. Tetsuya Mitsudomi from Kindai University School of Medicine in Japan. They shared insights on decision-making strategies for perioperative treatment, prognostic biomarkers, and managing adverse events in NSCLC immunotherapy.

ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients

By Mourabit Halima 2024.10.20

Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances in perioperative immunotherapy and combination immunotherapy for MIUC patients. Dr. Wei Yu and Dr. Qi Tang from Peking University First Hospital shared their insights on this important topic.

Dr. Hua Wang: New Approaches in Marginal Zone Lymphoma Treatment – Rethinking Chemotherapy-Free and Combination Strategies丨The 5th Tianjin International Lymphoma Symposium

By Mourabit Halima 2024.10.20

From September 6-8, 2024, the 5th Tianjin International Lymphoma Symposium was successfully held. The conference featured twelve specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Hua Wang from the Sun Yat-sen University Cancer Center to review the latest treatment strategies for marginal zone lymphoma (MZL).

Mesenchymal Stem Cell-Derived Exosomes Alleviate Liver Fibrosis

By Mourabit Halima 2024.10.20

Despite increasing knowledge of the cellular and molecular mechanisms underlying liver fibrosis, no Western medicine has been approved to treat the condition. Mesenchymal stem cells (MSCs), which are multipotent progenitor…

CUA 2024丨Dr. Shancheng Ren: “Super Veil Technique” in Extraperitoneal Single-Port Robotic Radical Prostatectomy Meets Patient Needs, Changhai Urology Continues to Tackle AI, Surgical Strategy, and Other Cutting-Edge Challenges

By Mourabit Halima 2024.10.19

Younger, low-risk prostate cancer patients often prioritize quality of life, particularly urinary control and sexual function, leading to ongoing clinical exploration for treatment strategies that meet these demands. From September 19 to 22, 2024, the 31st Urology Academic Conference was held at the National Convention Center in Tianjin. After the conference, Urology Frontier invited Dr. Shancheng Ren from The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) to discuss the advantages of extraperitoneal single-port robotic surgery, mastering surgical techniques, and the team's exploration of cutting-edge topics in urology.

CSCO 2024 | Pioneers in Melanoma Care Chart China’s Path to Personalized Therapies

By Mourabit Halima 2024.10.19

Although melanoma has a relatively low incidence among malignant tumors, its hidden onset and high malignancy make it a formidable disease. In recent years, targeted and immunotherapy treatments for solid tumors have developed rapidly, many of which began with melanoma and later extended to other cancers. However, there are significant biological differences between melanoma in Chinese and Western patients, necessitating the development of treatment protocols and standards tailored to Chinese and Asian patients. At the 2024 CSCO Conference, Dr. Jun Guo from Peking University Cancer Hospital, Dr. Xiaohui Niu from Beijing Jishuitan Hospital/National Center for Orthopedics, Dr. Di Wu from The First Bethune Hospital of Jilin University, and Dr. Lu Si from Peking University Cancer Hospital shared insights into the journey of melanoma diagnosis and treatment in China. They also reflected on the efforts of the CSCO Melanoma Expert Committee in establishing standardized treatment guidelines tailored to China’s needs.

CSCO 2024 | Pioneering Cellular Therapies and Precision Strategies in Ovarian Cancer

By Mourabit Halima 2024.10.19

The 2024 CSCO Ovarian Cancer Session covered various topics, including surgical treatment for ovarian cancer, drug therapy for advanced-stage patients, and data from novel drug research. Dr. Lingying Wu from the Cancer Hospital Chinese Academy of Medical Sciences chaired the session, where Dr. Oliver Dorigo from Stanford University delivered a report on “Cellular Therapy for Ovarian Cancer,” and Dr. Jianyu Rao from University of California, Los Angeles(UCLA) discussed “Precision Treatment Strategies for Ovarian Cancer.” After the session, the three experts participated in Oncology Frontier’s “CSCO International Perspectives” column, engaging in an in-depth discussion on cellular therapy and precision treatment strategies for ovarian cancer.

ESMO China’s Voice | Dr. Miaoyan Wei: Fruquintinib Combined with AG Regimen Offers Promising Conversion Therapy Strategy for Liver Metastases in PDAC

By Mourabit Halima 2024.10.19

The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as a first-line treatment for liver metastases in pancreatic ductal adenocarcinoma (PDAC). This study was featured in the poster session (Abstract #1529P). In this interview, Dr. Wei provides an in-depth analysis of the study's findings.